The group's research program focuses on basic and translational aspects of the pharmacology of immunomodulatory and antineoplastic agents. Research is focused on the identification and study of molecular and cellular characteristics useful for personalization of these therapies in pediatric patients. Through a combination of pharmacokinetic, pharmacodynamic and pharmacogenomic approaches, molecular and cellular characteristics and their association with patients' response to therapy are evaluated. In particular, investigations consider the personalization of therapy of pediatric inflammatory bowel disease, acute lymphoblastic leukemia, nephrotic syndrome and juvenile idiopathic arthritis.
